Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study

Park K.Haura E.B.Leighl N.B.Mitchell P.Shu C.A.Girard N.Viteri S.Han J.-Y.Kim S.-W.Lee C.K.Sabari J.K.Spira A.I.Yang T.-Y.Kim D.-W.Lee K.H.Sanborn R.E.Trigo J.Goto K.Lee J.-S.CHIH-HSIN YANGGovindan R.Bauml J.M.Garrido P.Krebs M.G.Reckamp K.L.Xie J.Curtin J.C.Haddish-Berhane N.Roshak A.Millington D.Lorenzini P.Thayu M.Knoblauch R.E.Cho B.C.2022-08-102022-08-1020210732-183Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85112311967&doi=10.1200%2fJCO.21.00662&partnerID=40&md5=e2ff9957343ed943510383c8c547b250https://scholars.lib.ntu.edu.tw/handle/123456789/616499[SDGs]SDG3Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i studyjournal article10.1200/JCO.21.00662343392922-s2.0-85112311967